Retinopatía secundaria a mieloma múltiple tratada con bevacizumab / Retinopathy secondary to multiple myeloma treated with bevacizumab
Arch. Soc. Esp. Oftalmol
; 95(10): 516-520, oct. 2020. ilus
Article
in Spanish
| IBECS
| ID: ibc-201405
Responsible library:
ES1.1
Localization: BNCS
RESUMEN
Mujer de 80 años con mieloma múltiple (MM) de tipo IgA, que desarrolló cambios retinianos semejantes a los de retinopatía diabética no proliferativa leve, objetivándose microaneurismas y fluido intrarretiniano. La paciente fue tratada con quimioterapia para MM e inyecciones intravítreas de bevacizumab, siendo controlada durante 22 meses. La terapia antiangiogénica puede ser útil en el control de retinopatía secundaria a MM siempre y cuando se realice el control de la enfermedad sistémica
ABSTRACT
The case is presented on an 80-year-old woman with IgA multiple myeloma (MM), who developed retinal changes similar to mild non-proliferative diabetic retinopathy, with micro-aneurysms and intraretinal fluid. The patient was treated with systemic chemotherapy for MM, and with bevacizumab intravitreal injections, with control of her ocular disorder for 22 months. Anti-angiogenic therapy can be useful in the control of retinopathy secondary to MM, as long as the systemic disease has been controlled
Search on Google
Collection:
National databases
/
Spain
Database:
IBECS
Main subject:
Bevacizumab
/
Microaneurysm
/
Multiple Myeloma
Limits:
Aged
/
Female
/
Humans
Language:
Spanish
Journal:
Arch. Soc. Esp. Oftalmol
Year:
2020
Document type:
Article
Institution/Affiliation country:
Consorci Sanitari de Terrassa/España